Clinical Trial Update: Trastuzumab for 6 Months or 1 Year in Treating Women With Nonmetastatic Breast Cancer That Can Be Removed By Surgery [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing 6 months versus 12 months of trastuzumab in women with nonmetastatic, surgically resectable breast cancer has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• HERCEPTIN (trastuzumab)

Snippet

Sponsor: National Cancer Institute, France | Conditions: Breast Cancer | Phase 3 | Status: COMPLETED